Under the agreement, Bionova will serve as the preferred manufacturing partner for Syenex’s best-in-class delivery platforms.

Bionova Scientific LLC, an Asahi Kasei company and a bespoke contract development and manufacturing organization (CDMO), announced a strategic manufacturing alliance with Syenex, a genetic medicines ...

AGC Biologics signed a licensing agreement to use Asimov’s lentiviral packaging system, enabling production from a single-plasmid transfection.

Following U.S. and EU market authorization for Waskyra™, AGC Biologics will continue to support the commercial development of the gene therapy.

With the decision by the U.S. Food and Drug Administration and the European Commission to grant market authorization for Waskyratm, a gene therapy to treat Wiskott-Aldrich syndrome, AGC Biologics' ...

Data indicate that the AutoCell platform could pave the way for CGTs for the first time as first-line therapies.

For most of human history, viruses have been our unseen enemies—particles of RNA and DNA that hijack our cells. Yet a more astonishing truth lies quietly within us: Nearly 8% of the human genome is ...

Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality ...

Detailed price information for Oxford Biomedica Plc (OXBDF) from The Globe and Mail including charting and trades.

So far, the BCMA-targeted CAR has shown early success in four Australian multiple myeloma patients in a Phase I trial.

The US FDA approved 46 new drugs in 2025, despite a tumultuous year at the regulatory agency.